Merck responds to Arcoxia approvable letter
James G. Dickinson
January 01 2007
Merck has responded to an FDA “approvable” letter for Arcoxia (etoricoxib), an investigational selective Cox-2 inhibitor, with results of the ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.